Current Psychiatry Reports

, Volume 2, Issue 6, pp 490–494

The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse

  • Charles L. Bowden
Article

Abstract

Bipolar disorder is marked by frequent recurrences, a course from childhood or early adulthood until death, marked increased rates of suicide, and substantial functional morbidity. Maintenance treatment is generally recommended to reduce the ravages of the illness. This article reviews the evidence that lithium, divalproex, and carbamazepine may reduce suicidal risk. It reviews the evidence for relapse prevention for lithium, valproate, and other drugs often employed in the maintenance phase treatment of bipolar disorder. Both lithium and divalproex appear beneficial in prevention of relapse, although recent studies indicate more modest effects for lithium than did early studies from the 1970s.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997, 170:205–228.PubMedGoogle Scholar
  2. 2.
    Dilsaver SC, Chen YW, Swann AC, et al.: Suicidality in patients with pure and depressive mania. Am J Psychiatry 1994, 151:1312–1315.PubMedGoogle Scholar
  3. 3.
    Müller-Oerlinghausen B, Muser CB, Volk J: Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992, 25:261–269.PubMedCrossRefGoogle Scholar
  4. 4.
    Simpson SG, Jamison KR: The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999, 60 Suppl 2:53–56.PubMedGoogle Scholar
  5. 5.
    Ahrens B, Müller-Oerlinghausen B, Grof P: Length of lithium treatment needed to eliminate the high mortality of affective disorders. Br J Psychiatry 1993, 163 Suppl 21:27–29.Google Scholar
  6. 6.
    Isometsa ET, Henriksson MM, Aro HM, Lonnqvist JK: Suicide in bipolar disorder in Finland. Am J Psychiatry 1994, 151:1020–1024.PubMedGoogle Scholar
  7. 7.
    Tondo L, Baldessarini RJ, Hennen J, et al.: Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998, 59:405–414.PubMedGoogle Scholar
  8. 8.
    Baldessarini RJ, Tondo L, Floris G, Rudas N: Reduced morbidity after gradually discontinuing lithium in bipolar I and II disorders: a replication study. Am J Psychiatry 1997, 154:551–553.PubMedGoogle Scholar
  9. 9.
    Theis-Flechtner K, Müller-Oerlinghausen B, Seibert W, et al.: Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 1996, 29:103–107.Google Scholar
  10. 10.
    Greil W, Ludwig-Mayerhofer W, Erazo N, et al.: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997, 43:151–161.PubMedCrossRefGoogle Scholar
  11. 11.
    Prien RF, Caffey EM, Klett CJ: Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 1973, 28:337–341.PubMedGoogle Scholar
  12. 12.
    Vestergaard P, Aagaard J: Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991, 21:33–38.PubMedCrossRefGoogle Scholar
  13. 13.
    Bowden CL, Calabrese JR, McElroy SL, et al.: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000, 57:481–489. A large (n = 372) randomized study that provides the only blinded comparison of lithium with a mood stabilizer, and the only study to taper the mood stabilizer taken at the time of randomization, to reduce possibility of drug withdrawal-induced relapse.PubMedCrossRefGoogle Scholar
  14. 14.
    Gitlin MJ, Swendsen J, Heller TL, Hammen C: Relapse and impairment in bipolar disorder. Am J Psychiatry 1995, 152:1635–1640.PubMedGoogle Scholar
  15. 15.
    Coppen A, Noguera R, Bailey J, et al.: Prophylactic lithium in affective disorders. Lancet 1971, 2:275–279.PubMedCrossRefGoogle Scholar
  16. 16.
    Cundall RL, Brooks PW, Murray LG: A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972, 2:308–311.PubMedCrossRefGoogle Scholar
  17. 17.
    Baastrup PC, Poulsen JC, Schou M, et al.: Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent-depressive disorder. Lancet 1970, 2:326–330.PubMedCrossRefGoogle Scholar
  18. 18.
    Melia PI: Prophylactic lithium: a double-blind trial in recurrent affective disorders. Br J Psychiatry 1970, 116:621–624.PubMedGoogle Scholar
  19. 19.
    Stallone F, Shelley E, Mendlewicz J, Fieve RR: The use of lithium in affective disorders, III: a double-blind study of prophylaxis in bipolar disorder. Am J Psychiatry 1973, 130:1006–1010.PubMedGoogle Scholar
  20. 20.
    Aagaard J, Vestergaard P: Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord 1990, 18:259–266.PubMedCrossRefGoogle Scholar
  21. 21.
    Tohen M, Watenaux CM, Tsuang MT: Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990, 47:1106–1111.PubMedGoogle Scholar
  22. 22.
    Harrow M, Goldberg JF, Grossman LS, Meltzer HY: Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990, 47:665–671.PubMedGoogle Scholar
  23. 23.
    Maj M, Pirozzi R, Magliano L, Bartoli L: Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998, 155:30–35. A systematic report of long-term outcomes with lithium treatment of bipolar disorder. It indicates good results among patients who stay with treatment for several years, but high rates of early failure, poor adherence, and dropouts.PubMedGoogle Scholar
  24. 24.
    Schou M, Juel-Nielsen N, Stromgren E, Voldby H: The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954, 17:250–260.PubMedGoogle Scholar
  25. 25.
    Maggs R: Treatment of manic illness with lithium carbonate. Br J Psychiatry 1963, 109:56–65.Google Scholar
  26. 26.
    Goodwin FK, Murphy DL, Bunney WE Jr: Lithium carbonate treatment in depression and mania: a longitudinal doubleblind study. Arch Gen Psychiatry 1969, 21:486–496.PubMedGoogle Scholar
  27. 27.
    Stokes PE, Shamoian CA, Stoll PM, Patton MJ: Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971, 1:1319–1325.PubMedCrossRefGoogle Scholar
  28. 28.
    Bowden CL, Brugger AM, Swann AC, et al.: Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 1994, 271:918–924.PubMedCrossRefGoogle Scholar
  29. 29.
    Esparon J, Kolloori J, Naylor GJ, et al.: Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986, 148:723–725.PubMedCrossRefGoogle Scholar
  30. 30.
    Ahlfors UG, Baastrup PC, Dencker SJ: Flupenthixol decanoate in recurrent manic-depressive illness: a comparison with lithium. Acta Psychiatr Scand 1981, 64:226–237.PubMedGoogle Scholar
  31. 31.
    Okuma T, Yamashita I, Takahashi R, et al.: Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990, 23:143–150.PubMedCrossRefGoogle Scholar
  32. 32.
    Lambert PA, Venaud D: Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders. Nervure 1992, 5:57–65.Google Scholar
  33. 33.
    Calabrese JR, Delucchi GA: Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990, 147:431–434.PubMedGoogle Scholar
  34. 34.
    McElroy SL, Keck Jr, Pope Jr. HG: Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987, 7:16–24.PubMedGoogle Scholar
  35. 35.
    Baldessarini RJ, Tohen M, Tondo L: Maintenance treatment in bipolar disorder [comment]. Arch Gen Psychiatry 2000, 57:490–492. A thoughtful editorial on the complexities of analysis of treatments for prophylaxis of bipolar disorder, with special attention to the difficulties of studying a sample fully representative of the spectrum of bipolar disorder.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Charles L. Bowden
    • 1
  1. 1.The University of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations